A Phase 2 interventional study of brentuximab vedotin and rituximab in Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 34 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 7th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 3
First in 2006; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 58 across the 25 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 176 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: brentuximab vedotin · Drug: rituximab
Drug: brentuximab vedotin
1.8 mg/kg every 3 weeks by IV infusion
Also known as: Adcetris; SGN-35
375 mg/m2 every 3 weeks by IV infusion
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy
Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 3 years
Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Time frame: Up to 3 years
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab
Percentage of participants treated with brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 3 years
Complete Remission (CR) Rate by Investigator
Percentage of participants treated with brentuximab vedotin monotherapy or brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 3 years
Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
Duration of complete remission (CR) or partial remission (PR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 3 years
Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
Duration of complete remission (CR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 3 years
Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause
Time frame: Up to approximately 3 years
Correlation Between Antitumor Activity of Brentuximab Vedotin Monotherapy and CD30 Expression
Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), or stable disease (SD, no new sites and no change in size of previous lesions) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma. Patients are grouped by CD30-positivity or CD30u (undetectable CD30).
Time frame: Up to 3 years
Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Monotherapy
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Time frame: Up to 3 years
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)
End of infusion concentration of ADC following the first dose of brentuximab vedotin
Time frame: 1 day
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)
Trough concentration of ADC from 0 to 21 days following the first dose of brentuximab vedotin
Time frame: 3 weeks
Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)
Maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin
Time frame: 3 weeks
Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
Time of maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin
Time frame: 3 weeks
Baseline Soluble CD30 Expression
Serum concentration of soluble CD30 before first dose of brentuximab vedotin
Time frame: Baseline
Aug 2011 - Jun 2015
| Milestone | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R |
|---|---|---|---|---|
| Started | 35 | 68 | 53 | 16 |
| Completed | 35 | 66 | 51 | 15 |
| Not completed | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV |
|---|---|---|---|---|
| Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy | 41 (24.6 to 59.3) | 26 (9.1 to 51.2) | 44 (29.5 to 58.8) | 31 (18.7 to 45.1) |
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
| participants | CD30+ DLBCL, BV+R |
|---|---|
| Any TEAE | 16 |
| TEAE Related to Study Drug | 15 |
| TEAE With Severity Grade >/=3 | 9 |
| Discontinued Treatment Due to Adverse Event | 2 |
| Serious Adverse Event | 3 |
| Serious Adverse Event Related to Study Drug | 3 |
| Deaths (Within 30 Days of Last Dose) | 1 |
| Chemistry Laboratory Abnormalities >/=Grade 3 | 1 |
| Hematology Laboratory Abnormalities >/=Grade 3 | 7 |
Percentage of participants treated with brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | CD30+ DLBCL, BV+R |
|---|---|
| Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab | 50 (21.1 to 78.9) |
Percentage of participants treated with brentuximab vedotin monotherapy or brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R |
|---|---|---|---|---|---|
| Complete Remission (CR) Rate by Investigator | 24 (10.7 to 41.2) | 16 (3.4 to 39.6) | 19 (8.9 to 32.6) | 12 (4.4 to 23.4) | 17 (2.1 to 48.4) |
Duration of complete remission (CR) or partial remission (PR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| months | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV |
|---|---|---|---|---|
| Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis | 7.6 (1.3 to 36.1) | 1.6 (1.4 to 34) | 4.7 (0 to 22.7) | 4.7 (0.5 to 11.6) |
Duration of complete remission (CR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| months | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV |
|---|---|---|---|---|
| Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis | NA (1.8 to NA) | 7.2 (1.6 to 34) | NA (2.2 to NA) | 11.6 (1.4 to 11.6) |
Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause
| months | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV |
|---|---|---|---|---|
| Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis | 2.5 (0.3 to 37.4) | 2.9 (0.6 to 36.3) | 4.0 (0.6 to 24.0) | 1.4 (0.4 to 15.6) |
Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), or stable disease (SD, no new sites and no change in size of previous lesions) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma. Patients are grouped by CD30-positivity or CD30u (undetectable CD30).
| percentage of participants | CD30+ T-Cell NHL, BV | CD30+ Other B-Cell NHL, BV | CD30+ DLBCL, BV | CD30u DLBCL, BV |
|---|---|---|---|---|
| Complete Remission (CR) | 24 (10.7 to 41.2) | 16 (3.4 to 39.6) | 19 (8.9 to 32.6) | 12 (4.4 to 23.4) |
| Partial Remission (PR) | 18 (6.8 to 34.5) | 11 (1.3 to 33.1) | 25 (13.6 to 39.6) | 19 (9.6 to 32.5) |
| Disease Control Rate (CR+PR+SD) | 59 (40.7 to 75.4) | 63 (38.4 to 83.7) | 69 (53.7 to 81.3) | 42 (28.7 to 56.8) |
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
| participants | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Any TEAE | 32 | 66 | 52 |
| TEAE Related to Study Drug | 28 | 62 | 39 |
| TEAE With Severity Grade >/=3 | 23 | 52 | 37 |
| Discontinued Treatment Due To Adverse Event | 6 | 7 | 4 |
| Serious Adverse Event | 15 | 34 | 22 |
| Serious Adverse Event Related to Study Drug | 5 | 15 | 7 |
| Deaths (Within 30 Days of Last Dose) | 3 | 5 | 6 |
| Chemistry Laboratory Abnormalities >/= Grade 3 | 8 | 16 | 10 |
| Hematology Laboratory Abnormalities >/= Grade 3 | 11 | 31 | 21 |
End of infusion concentration of ADC following the first dose of brentuximab vedotin
| ug/mL | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1) | 35.6 ± 25 | 40.0 ± 29 | 40.1 ± 43 |
Trough concentration of ADC from 0 to 21 days following the first dose of brentuximab vedotin
| ug/mL | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1) | 0.44 ± 113 | 0.91 ± 119 | 0.86 ± 94 |
Maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin
| ng/mL | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1) | 4.71 ± 63 | 4.66 ± 88 | 3.95 ± 74 |
Time of maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin
| days | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) | 1.90 (0.88 to 6.89) | 1.91 (0.91 to 20.90) | 1.94 (0.93 to 19.8) |
Serum concentration of soluble CD30 before first dose of brentuximab vedotin
| ng/mL | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV |
|---|---|---|---|
| Baseline Soluble CD30 Expression | 1005.4 (89.4 to 26426.6) | 229.4 (33.2 to 21277.7) | 140.4 (53.4 to 1695.9) |
Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD30+ NHL (T-Cell and B-Cell), BV | — | 49/103 (47.6%) | 96/103 (93.2%) |
| CD30u DLBCL, BV | — | 22/53 (41.5%) | 48/53 (90.6%) |
| CD30+ DLBCL, BV+R | — | 3/16 (18.8%) | 15/16 (93.8%) |
| Event | CD30+ NHL (T-Cell and B-Cell), BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R |
|---|---|---|---|
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/103 | 6/53 | 0/16 |
| PyrexiaGeneral disorders | 9/103 | 0/53 | 0/16 |
| PneumoniaInfections and infestations | 8/103 | 3/53 | 0/16 |
| Escherichia urinary tract infectionInfections and infestations | 0/103 | 0/53 | 1/16 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/103 | 2/53 | 1/16 |
| HyponatremiaMetabolism and nutrition disorders | 1/103 | 1/53 | 1/16 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/103 | 0/53 | 1/16 |
| Mental status changesPsychiatric disorders | 0/103 | 0/53 | 1/16 |
| Sinus tachycardiaCardiac disorders | 0/103 | 1/53 | 1/16 |
| Toxic epidermal necrolysisSkin and subcutaneous tissue disorders | 0/103 | 0/53 | 1/16 |
| Event | CD30+ NHL (T-Cell and B-Cell), BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R |
|---|---|---|---|
| NauseaGastrointestinal disorders | 28/103 | 17/53 | 8/16 |
| FatigueGeneral disorders | 43/103 | 17/53 | 4/16 |
| NeutropeniaBlood and lymphatic system disorders | 31/103 | 13/53 | 6/16 |
| VomtingGastrointestinal disorders | 19/103 | 11/53 | 6/16 |
| Peripheral sensory neuropathyNervous system disorders | 33/103 | 14/53 | 6/16 |
| DiarrheaGastrointestinal disorders | 33/103 | 9/53 | 4/16 |
| PyrexiaGeneral disorders | 22/103 | 12/53 | 5/16 |
| ConstipationGastrointestinal disorders | 19/103 | 15/53 | 2/16 |
| ChillsGeneral disorders | 11/103 | 3/53 | 4/16 |
| PruritusSkin and subcutaneous tissue disorders | 13/103 | 5/53 | 4/16 |
All participants who received treatment.
| Age, Continuous(years) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Median | 64 (33 to 83) | 57 (16 to 85) | 65 (21 to 91) | 62 (22 to 78) | 63 (16 to 91) |
| Sex: Female, Male(Participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Female | 8 | 29 | 27 | 4 | 68 |
| Male | 27 | 39 | 26 | 12 | 104 |
| Ethnicity (NIH/OMB)(Participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 7 | 1 | 14 |
| Not Hispanic or Latino | 32 | 65 | 46 | 15 | 158 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 2 |
| Asian | 1 | 3 | 4 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 5 | 6 | 4 | 0 | 15 |
| White | 29 | 55 | 41 | 15 | 140 |
| More than one race | 0 | 3 | 2 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Pathological Diagnosis(participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma (DLBCL) | 0 | 43 | 53 | 16 | 112 |
| Epstein-Barr Virus-Associated DLBCL of Elderly | 0 | 5 | 0 | 0 | 5 |
| Follicular Lymphoma | 0 | 3 | 0 | 0 | 3 |
| Gray Zone Lymphoma | 0 | 6 | 0 | 0 | 6 |
| Primary Mediastinal B-Cell Lymphoma | 0 | 6 | 0 | 0 | 6 |
| Post-Transplant Lymphoproliferative Disorder | 0 | 3 | 0 | 0 | 3 |
| Plasmablastic Lymphoma | 0 | 1 | 0 | 0 | 1 |
| T-Cell Rich B-Cell Lymphoma | 0 | 1 | 0 | 0 | 1 |
| Angioimmunoblastic T-cell Lymphoma | 13 | 0 | 0 | 0 | 13 |
| Peripheral T-Cell Lymphoma Not Otherwise Specified | 22 | 0 | 0 | 0 | 22 |
| Transformed Disease from Prior Non-Hodgkin Lymphoma(participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Yes | 1 | 14 | 11 | 5 | 31 |
| No | 34 | 54 | 42 | 11 | 141 |
| Disease Stage(participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Stage I | 2 | 4 | 1 | 1 | 8 |
| Stage II | 2 | 12 | 7 | 3 | 24 |
| Stage III | 13 | 17 | 11 | 6 | 47 |
| Stage IV | 14 | 31 | 33 | 6 | 84 |
| Unknown | 4 | 4 | 1 | 0 | 9 |
| Bulky Disease (≥5 cm on at least one baseline index lesion)(participants) | CD30+ T-Cell NHL, BV | CD30+ B-Cell NHL, BV | CD30u DLBCL, BV | CD30+ DLBCL, BV+R | Total |
|---|---|---|---|---|---|
| Yes | 5 | 27 | 35 | 4 | 71 |
| No | 30 | 41 | 18 | 12 | 101 |
4 further baseline measures are reported on the registry.
The record gives a start of Aug 2011, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large B-Cell, Diffuse →